![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Herve; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiying; Macharia, Harrison; Trask, Peter; Song, Chunyan; Winer, Eric P. und Harbeck, Nadia
(2022):
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
In: Journal of Clinical Oncology, Bd. 40, Nr. 5: S. 438-448
2021
Winer, Eric P.; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Zhou, Xuan; Karantza, Vassiliki; Mejia, Jaime und Cortes, Javier
(2021):
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
In: Lancet Oncology, Bd. 22, Nr. 4: S. 499-511